Managing the clinical effects of drug-induced intestinal dysbiosis with a focus to antibiotics: Challenges and opportunities

The term intestinal dysbiosis is used for indicating change(s) of the intestinal microbiota which have been associated with the development of diseases and the deterioration of disease treatments in humans. In this review, documented clinical effects of drug-induced intestinal dysbiosis are briefly presented, and methodologies which could be considered for the management of drug-induced intestinal dysbiosis based on clinical data are critically reviewed. Until relevant methodologies are optimized and/or their effectiveness to the general population is confirmed, and, since drug-induced intestinal dysbiosis refers predominantly to antibiotic-specific intestinal dysbiosis, a pharmacokinetically-based approach for mitigating the impact of antimicrobial therapy on intestinal dysbiosis is proposed.

Automated summary

Intestinal dysbiosis refers to changes in the intestinal microbiota that are associated with the development and worsening of diseases in humans. This review briefly presents the clinical effects of drug-induced intestinal dysbiosis and critically reviews methodologies for managing it based on clinical data. A pharmacokinetically-based approach is proposed for mitigating the impact of antimicrobial therapy on intestinal dysbiosis, but further optimization and confirmation of effectiveness to the general population are needed.